[1] Mishra PJ, Bertino JR. MicroRNA polymorphisms: the future of pharmacogenomics, molecular epidemiology and individualized medicine. Pharmacogenomics, 2009, 10(3): 399–416.
[2] Horikawa Y, Wood CG, Yang HS, Zhao H, Ye YQ, Gu J, Lin J, Habuchi T, Wu XF. Single nucleotide polymor-phisms of microRNA machinery genes modify the risk of renal cell carcinoma. Clin Cancer Res, 2008, 14(23): 7956–7962.
[3] Yang HS, Dinney CP, Ye YQ, Zhu Y, Grossman HB, Wu XF. Evaluation of genetic variants in microRNA-related genes and risk of bladder cancer. Cancer Res, 2008, 68(7): 2530–2537.
[4] Gottwein E, Cai XZ, Cullen BR. A novel assay for viral microRNA function identifies a single nucleotide poly-morphism that affects Drosha processing. J Virol, 2006, 80(11): 5321–5326.
[5] Duan RH, Pak CH, Jin P. Single nucleotide polymorphism associated with mature miR-125a alters the processing of pri-miRNA. Hum Mol Genet, 2007, 16(9): 1124–1131.
[6] Wu MQ, Jolicoeur N, Li Z, Zhang LH, Fortin Y, L'Abbe D, Yu ZB, Shen SH. Genetic variations of microRNAs in human cancer and their effects on the expression of miRNAs. Carcinogenesis, 2008, 29(9): 1710–1716.
[7] Mencía Á, Modamio-Høybjør S, Redshaw N, Morín M, Mayo-Merino F, Olavarrieta L, Aguirre LA, del Castillo I, Steel KP, Dalmay T, Moreno F, Moreno-Pelayo MÁ. Mu-tations in the seed region of human miR-96 are responsi-ble for nonsyndromic progressive hearing loss. Nat Genet, 2009, 41(5): 609–613.
[8] Li W, Duan R, Kooy F, Sherman SL, Zhou W, Jin P.Germline mutation of microRNA-125a is associated with breast cancer. J Med Genet, 2009, 46(5): 358–360.
[9] Pfister S, Remke M, Castoldi M, Bai AHC, Muckenthaler MU, Kulozik A, von Deimling A, Pscherer A, Lichter P, Korshunov A. Novel genomic amplification targeting the microRNA cluster at 19q13.42 in a pediatric embryonal tumor with abundant neuropil and true rosettes. Acta Neuropathol, 2009, 117(4): 457–464.
[10] Bandi N, Zbinden S, Gugger M, Arnold M, Kocher V, Hasan L, Kappeler A, Brunner T, Vassella E.miR-15a and miR-16 are implicated in cell cycle regulation in a Rb-dependent manner and are frequently deleted or down-regulated in non-small cell lung cancer. Cancer Res, 2009, 69(13): 5553–5559.
[11] Diederichs S, Haber DA.Sequence variations of microR-NAs in human cancer: alterations in predicted secondary structure do not affect processing. Cancer Res, 2006, 66(12): 6097–6104.
[12] Kontorovich T, Levy A, Korostishevsky M, Nir U, Fried-man E. Single nucleotide polymorphisms in miRNA bind-ing sites and miRNA genes as breast/ovarian cancer risk modifiers in Jewish high-risk women. Int J Cancer, 2010, 127(3): 589–597.
[13] Iorio MV, Visone R, Di Leva G, Donati V, Petrocca F, Casal-ini P, Taccioli C, Volinia S, Liu CG, Alder H, Calin GA, Mé-nard S, Croce CM. MicroRNA signatures in human ovarian cancer. Cancer Res, 2007, 67(18): 8699–8707.
[14] Bandres E, Agirre X, Bitarte N, Ramirez N, Zarate R, Roman-Gomez J, Prosper F, Garcia-Foncillas J. Epigenetic regulation of microRNA expression in colorectal cancer. Int J Cancer, 2009, 125(11): 2737–2743.
[15] Abelson JF, Kwan KY, O'Roak BJ, Baek DY, Stillman AA, Morgan TM, Mathews CA, Pauls DL, Rasin MR, Gunel M, Davis NR, Ercan-Sencicek AG, Guez DH, Spertus JA, Leckman JF, Dure LS 4th, Kurlan R, Singer HS, Gilbert DL, Farhi A, Louvi A, Lifton RP, Šestan N, State MW. Sequence variants in SLITRK1 are associated with Tou-rette's syndrome. Science, 2005, 310(5746): 317–320.
[16] He HL, Jazdzewski K, Li W, Liyanarachchi S, Nagy R, Volinia S, Calin GA, Liu CG, Franssila K, Suster S, Kloos RT, Croce CM, de la Chapelle A. The role of microRNA genes in papillary thyroid carcinoma. Proc Natl Acad Sci USA, 2005, 102(52): 1
